Cargando…

The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma

Cancer genomics and cancer mutation databases have made an available wealth of information about missense mutations found in cancer patient samples. Contextualizing by means of annotation and predicting the effect of amino acid change help identify which ones are more likely to have a pathogenic imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiberti, Matteo, Di Leo, Luca, Vistesen, Mette Vixø, Kuhre, Rikke Sofie, Cecconi, Francesco, De Zio, Daniela, Papaleo, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569343/
https://www.ncbi.nlm.nih.gov/pubmed/36243772
http://dx.doi.org/10.1038/s41419-022-05318-2
_version_ 1784809834730749952
author Tiberti, Matteo
Di Leo, Luca
Vistesen, Mette Vixø
Kuhre, Rikke Sofie
Cecconi, Francesco
De Zio, Daniela
Papaleo, Elena
author_facet Tiberti, Matteo
Di Leo, Luca
Vistesen, Mette Vixø
Kuhre, Rikke Sofie
Cecconi, Francesco
De Zio, Daniela
Papaleo, Elena
author_sort Tiberti, Matteo
collection PubMed
description Cancer genomics and cancer mutation databases have made an available wealth of information about missense mutations found in cancer patient samples. Contextualizing by means of annotation and predicting the effect of amino acid change help identify which ones are more likely to have a pathogenic impact. Those can be validated by means of experimental approaches that assess the impact of protein mutations on the cellular functions or their tumorigenic potential. Here, we propose the integrative bioinformatic approach Cancermuts, implemented as a Python package. Cancermuts is able to gather known missense cancer mutations from databases such as cBioPortal and COSMIC, and annotate them with the pathogenicity score REVEL as well as information on their source. It is also able to add annotations about the protein context these mutations are found in, such as post-translational modification sites, structured/unstructured regions, presence of short linear motifs, and more. We applied Cancermuts to the intrinsically disordered protein AMBRA1, a key regulator of many cellular processes frequently deregulated in cancer. By these means, we classified mutations of AMBRA1 in melanoma, where AMBRA1 is highly mutated and displays a tumor-suppressive role. Next, based on REVEL score, position along the sequence, and their local context, we applied cellular and molecular approaches to validate the predicted pathogenicity of a subset of mutations in an in vitro melanoma model. By doing so, we have identified two AMBRA1 mutations which show enhanced tumorigenic potential and are worth further investigation, highlighting the usefulness of the tool. Cancermuts can be used on any protein targets starting from minimal information, and it is available at https://www.github.com/ELELAB/cancermuts as free software.
format Online
Article
Text
id pubmed-9569343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95693432022-10-17 The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma Tiberti, Matteo Di Leo, Luca Vistesen, Mette Vixø Kuhre, Rikke Sofie Cecconi, Francesco De Zio, Daniela Papaleo, Elena Cell Death Dis Article Cancer genomics and cancer mutation databases have made an available wealth of information about missense mutations found in cancer patient samples. Contextualizing by means of annotation and predicting the effect of amino acid change help identify which ones are more likely to have a pathogenic impact. Those can be validated by means of experimental approaches that assess the impact of protein mutations on the cellular functions or their tumorigenic potential. Here, we propose the integrative bioinformatic approach Cancermuts, implemented as a Python package. Cancermuts is able to gather known missense cancer mutations from databases such as cBioPortal and COSMIC, and annotate them with the pathogenicity score REVEL as well as information on their source. It is also able to add annotations about the protein context these mutations are found in, such as post-translational modification sites, structured/unstructured regions, presence of short linear motifs, and more. We applied Cancermuts to the intrinsically disordered protein AMBRA1, a key regulator of many cellular processes frequently deregulated in cancer. By these means, we classified mutations of AMBRA1 in melanoma, where AMBRA1 is highly mutated and displays a tumor-suppressive role. Next, based on REVEL score, position along the sequence, and their local context, we applied cellular and molecular approaches to validate the predicted pathogenicity of a subset of mutations in an in vitro melanoma model. By doing so, we have identified two AMBRA1 mutations which show enhanced tumorigenic potential and are worth further investigation, highlighting the usefulness of the tool. Cancermuts can be used on any protein targets starting from minimal information, and it is available at https://www.github.com/ELELAB/cancermuts as free software. Nature Publishing Group UK 2022-10-15 /pmc/articles/PMC9569343/ /pubmed/36243772 http://dx.doi.org/10.1038/s41419-022-05318-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Tiberti, Matteo
Di Leo, Luca
Vistesen, Mette Vixø
Kuhre, Rikke Sofie
Cecconi, Francesco
De Zio, Daniela
Papaleo, Elena
The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
title The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
title_full The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
title_fullStr The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
title_full_unstemmed The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
title_short The Cancermuts software package for the prioritization of missense cancer variants: a case study of AMBRA1 in melanoma
title_sort cancermuts software package for the prioritization of missense cancer variants: a case study of ambra1 in melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569343/
https://www.ncbi.nlm.nih.gov/pubmed/36243772
http://dx.doi.org/10.1038/s41419-022-05318-2
work_keys_str_mv AT tibertimatteo thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT dileoluca thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT vistesenmettevixø thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT kuhrerikkesofie thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT cecconifrancesco thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT deziodaniela thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT papaleoelena thecancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT tibertimatteo cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT dileoluca cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT vistesenmettevixø cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT kuhrerikkesofie cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT cecconifrancesco cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT deziodaniela cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma
AT papaleoelena cancermutssoftwarepackagefortheprioritizationofmissensecancervariantsacasestudyofambra1inmelanoma